790 results on '"Johnson, Nathalie A."'
Search Results
102. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
103. Alternative Therapy Used as Primary Treatment for Breast Cancer Negatively Impacts Outcomes
104. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
105. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
106. Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma
107. Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab.
108. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
109. Abstract OT-16-01: A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
110. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy : KEYNOTE-087 subgroup analysis
111. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study
112. The uracil–DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID
113. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study
114. The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma
115. Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis
116. Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy
117. Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes
118. Abstract IA42: Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA
119. The Role of Molecular Imaging Technologies in Breast Cancer Diagnosis and Management
120. Neoadjuvant Therapy in Breast Cancer
121. B Cells With High Side Scatter Parameter by Flow Cytometry Correlate With Inferior Survival in Diffuse Large B-Cell Lymphoma
122. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
123. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival
124. The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID
125. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
126. Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.
127. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
128. Adequate sentinel node harvest is associated with low false negative rate in breast cancer managed with neoadjuvant chemotherapy and targeted axillary dissection
129. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates
130. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
131. KEYNOTE-204: A Multicentre, Randomised, Open-Label, Phase 3 Study of Pembrolizumab versus Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
132. Repression of LKB1 bymiR-17∼92sensitizesMYC-dependent lymphoma to biguanide treatment
133. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
134. Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP
135. Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL
136. Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance
137. Evaluation of T-Cell Compartment By Complex Multiparameter Flow Cytometry Reveals Distinct Patterns of T-Cell Exhaustion in DLBCL, FL and HL Patients
138. A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia
139. CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas
140. Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma
141. Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma
142. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
143. Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator for Adjuvant Therapy in Colon Cancer
144. Model-based clustering of array CGH data
145. Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator in Colon Cancer
146. Smoking-related disease on Australian television news: inaccurate portrayals may contribute to public misconceptions
147. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.
148. Do Mountain Bikers Know When They Have Had a Concussion and, Do They Know to Stop Riding?
149. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient
150. 'Hot water burns like fire'
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.